Retatrutide

Retatrutide is an investigational peptide drug developed by Eli Lilly and Company (Indianapolis, Indiana). It is a single synthetic peptide that acts as a triple hormone receptor agonist, activating three distinct targets simultaneously: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor. This triple-agonist mechanism distinguishes it from currently approved obesity medications, which target one (semaglutide: GLP-1 only) or two (tirzepatide: GLP-1 and GIP) receptors.

Retatrutide is designed for once-weekly subcutaneous injection. Its Phase 2 trial, published in the New England Journal of Medicine in 2023, reported mean body weight reductions of up to 24.2% at the highest dose (12 mg) over 48 weeks — a result that at the time represented the highest weight loss ever reported for an investigational drug in a published clinical trial. Phase 2 data also showed significant improvements in waist circumference, blood pressure, lipids, and glycemic markers.

As of April 2026, retatrutide is not approved by the U.S. Food and Drug Administration or any other regulatory agency for any indication. It is in Phase 3 clinical development under the TRIUMPH (TRIple agonist for Underlying Metabolic Problems with High weight) program, which includes trials for obesity, obstructive sleep apnea, and knee osteoarthritis. Lilly has reported early Phase 3 data showing 28.7% mean weight loss in the 12 mg arm over 80 weeks — the highest reported for any obesity drug in clinical development — and regulatory submission is expected in 2026.

Regulatory caution: Retatrutide is an investigational compound. It has not been reviewed for safety and efficacy at any dose for any indication outside of clinical trial protocols. Any use outside of a properly conducted clinical trial is unsanctioned and carries unknown risks.

Retatrutide's effects arise from simultaneous activation of three incretin and metabolic hormone receptor pathways:

• GLP-1 receptor agonism: GLP-1 (glucagon-like peptide-1) is an incretin hormone produced by intestinal L-cells. GLP-1 receptor activation stimulates glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon release, slows gastric emptying, and activates hypothalamic satiety centers — reducing appetite and food intake. This is the primary mechanism shared by semaglutide.
• GIP receptor agonism: GIP (glucose-dependent insulinotropic polypeptide) is produced by intestinal K-cells. GIP receptor activation amplifies glucose-stimulated insulin secretion and promotes favorable effects on adipose tissue metabolism. The synergistic combination of GLP-1 and GIP agonism — as seen with tirzepatide — produces greater weight loss than GLP-1 agonism alone. This additive effect is preserved in retatrutide.
• Glucagon receptor agonism: Glucagon is traditionally associated with raising blood glucose by stimulating hepatic glucose output. However, glucagon receptor activation also strongly stimulates hepatic fat oxidation (fat burning in the liver), increases energy expenditure, and promotes thermogenesis. When combined with GLP-1 agonism — which counteracts the hyperglycemic effect of glucagon — the metabolic benefits of glucagon receptor activation (increased energy expenditure and fat oxidation) can be captured without the glycemic downside. This third agonist component is what makes retatrutide mechanistically distinct from tirzepatide and is the proposed reason for its superior weight loss magnitude.

The net result of triple receptor activation is synergistic appetite suppression, enhanced insulin secretion, increased hepatic fat oxidation, and elevated energy expenditure — a combination that produces substantially greater caloric deficit and weight loss than dual or single receptor approaches.

The following potential benefits are based on Phase 2 human clinical trial data (NEJM 2023) and early Phase 3 data reported by Eli Lilly. All findings are from controlled clinical trials and may not be representative of uncontrolled use.

• Substantial body weight reduction: Phase 2 results showed mean weight loss of 17.5% (4 mg), 19.5% (8 mg), and 24.2% (12 mg) over 48 weeks at highest doses versus −2.1% placebo. Early Phase 3 TRIUMPH data reports approximately 28.7% in the 12 mg arm over 80 weeks — attributed to both the longer duration and potentially to the 80-week trial design capturing more plateau-resistant weight loss.
• Waist circumference reduction: Phase 2 participants showed clinically meaningful reductions in waist circumference — a proxy for visceral adiposity and cardiometabolic risk.
• Cardiometabolic improvements: Phase 2 demonstrated improvements in blood pressure, lipid profiles (LDL, triglycerides, HDL), and glycemic markers — effects expected given the mechanism and consistent with the GLP-1 drug class.
• Obstructive sleep apnea: TRIUMPH-OSA is a dedicated trial exploring retatrutide for obstructive sleep apnea — a condition strongly associated with obesity and for which weight loss produces meaningful symptom reduction.
• Knee osteoarthritis: TRIUMPH-OA evaluates whether the weight-loss and potential anti-inflammatory effects of retatrutide benefit knee osteoarthritis — a common comorbidity of obesity.
• Potentially greater weight loss plateau resistance: The glucagon receptor component may increase resting energy expenditure, which could partially counteract the metabolic adaptation (slowed metabolism) that limits long-term weight loss with GLP-1 agonists alone. This hypothesis is being evaluated in ongoing trials.

Retatrutide's safety profile in Phase 2 is broadly consistent with the GLP-1 drug class, with some important considerations related to its additional glucagon receptor activity.

• Gastrointestinal effects (most common): Nausea, vomiting, diarrhea, and constipation were the most frequently reported adverse effects in Phase 2, particularly during dose escalation. These are consistent with GLP-1 agonism and are typically transient. The highest-dose groups (8 mg, 12 mg) had higher rates of GI events than lower doses.
• Discontinuation rate: Phase 2 had a dose-dependent discontinuation rate due to adverse events: 3.9% (4 mg), 6.3% (8 mg), 16.2% (12 mg). The 12 mg group's higher discontinuation rate reflects the tolerability tradeoffs at maximum efficacy dosing.
• Heart rate increase: A modest dose-dependent increase in resting heart rate has been observed, consistent with glucagon receptor agonism. Mean increases of approximately 5–10 bpm were reported in Phase 2. This warrants monitoring in individuals with pre-existing cardiovascular conditions.
• Lipase and amylase elevations: Modest elevations in pancreatic enzymes were observed, as with other GLP-1 class drugs. No cases of pancreatitis were reported in Phase 2, but this remains a class-level concern to monitor.
• Muscle mass considerations: Rapid, large-magnitude weight loss with GLP-1 class drugs is associated with loss of lean mass alongside fat mass. Whether retatrutide's glucagon component affects lean mass differently than dual agonists is not yet established. High protein intake and resistance training are typically recommended to mitigate this risk.
• Unknown long-term safety: As an investigational compound, retatrutide's long-term safety profile — beyond Phase 2 follow-up — is not fully characterized. Phase 3 data and post-market surveillance (if approved) will establish the long-term risk picture.

The GLP-1 drug class carries a class-wide warning for thyroid C-cell tumors observed in rodents. Whether this translates to human risk is uncertain and under ongoing evaluation. Individuals with a personal or family history of medullary thyroid carcinoma or MEN-2 syndrome should not use GLP-1 agonist drugs.

Disclaimer: Retatrutide is investigational and not approved for any indication. The following doses are from published clinical trial protocols for educational purposes only. These are not recommendations for self-administration.

Phase 2 trial dose escalation protocol (subcutaneous injection, once weekly):

• 1 mg: Starting dose for all participants; 4 weeks at this dose
• 2 mg: Week 4–8 escalation
• 4 mg: Maintenance dose for the lowest experimental group
• 8 mg: Intermediate maintenance dose
• 12 mg: Maximum maintenance dose — highest efficacy, highest adverse event rate

Dose escalation in the trial was conducted gradually over several months to improve tolerability. The Phase 3 TRIUMPH program includes maintenance dosing at 4 mg and 9 mg in addition to 12 mg to characterize the dose-response relationship more fully.

Retatrutide has the most promising efficacy signal of any investigational obesity drug in clinical development as of 2026, though Phase 3 primary endpoint data has not yet been fully peer-reviewed and published.

• Phase 2 (NEJM 2023): The pivotal Phase 2 trial enrolled 338 adults with obesity (BMI ≥ 30) or overweight with comorbidities. Over 48 weeks, mean weight loss was dose-dependent: 17.5% (4 mg), 19.5% (8 mg), 24.2% (12 mg) versus −2.1% placebo. These results were published in the New England Journal of Medicine in 2023 and garnered significant attention for exceeding all prior published obesity drug results at that time.
• Phase 3 TRIUMPH program: Lilly launched the TRIUMPH clinical program in 2023–2024, comprising multiple trials: TRIUMPH-1 (obesity/overweight), TRIUMPH-OSA (obstructive sleep apnea), TRIUMPH-OA (knee osteoarthritis). The TRIUMPH program uses both 9 mg and 12 mg maintenance doses over 80 weeks. Early TRIUMPH data reporting 28.7% weight loss in the 12 mg arm was presented in 2026 but has not yet been fully peer-reviewed and published.
• Regulatory timeline: Lilly has stated that it expects to file a New Drug Application (NDA) with the FDA for retatrutide in 2026 or early 2027. FDA review timelines are typically 6–12 months for priority review designations, which retatrutide would likely qualify for. Regulatory approval, if granted, is not anticipated before 2027.
• Comparative context: In published Phase 3 data, tirzepatide (Mounjaro/Zepbound) achieved up to 22.5% mean weight loss over 72 weeks. Semaglutide (Wegovy) achieved approximately 15% over 68 weeks. Retatrutide's 24.2% Phase 2 result and early Phase 3 signals suggest it may represent a meaningful step above current approved options — but head-to-head trial data does not yet exist.

As of April 2026, retatrutide is an investigational new drug (IND) in active Phase 3 clinical development. It has not received FDA approval, EMA approval, or approval from any other regulatory agency for any indication.

• United States: Investigational. Available only within approved clinical trial protocols. Not compoundable — it is a large-molecule biologic manufactured under proprietary processes, not a simple compound that pharmacy compounders can legally replicate.
• European Union: No regulatory status established. Phase 3 trials are ongoing.
• Off-label or grey market access: Unlike some peptides that have been available through compounding pharmacies, retatrutide's status as a proprietary large-molecule drug makes unauthorized access extremely limited. Any source claiming to supply retatrutide outside of a clinical trial should be regarded with serious skepticism — identity, purity, and safety of such products cannot be verified.
• Expected timeline: NDA filing expected 2026. If approved on standard priority review, market availability could come in late 2027 at the earliest. This is speculative and depends on the outcome of regulatory review.